Skip to main content
PMC home page
Epidemiology and Infection logoLink to Epidemiology and Infection
. 1990 Feb;104(1):143–149. doi: 10.1017/s0950268800054625

Immunogenicity of yeast-derived hepatitis B vaccine from two different producers.

E Dahl-Hansen 1, J C Siebke 1, S S Frøland 1, M Degré 1
PMCID: PMC2271739  PMID: 2137785

Abstract

The immunogenicity and reactogenicity of two preparations of yeast-derived hepatitis B vaccines were compared in healthy adult populations. The two groups were vaccinated in parallel, but they were not matched for age and sex. All subjects seroconverted, and 9 months after the first vaccine dose, all had anti HBs titres of at least 10 IU/l. The anti-HBs titres were higher in the group of subjects given 20 micrograms vaccine antigen made by Smith Kline & RIT (GMT 2943 at 9 months) compared to those who received 10 micrograms of vaccine made by Merck, Sharp & Dohme (GMT 729 at 9 months). Adverse effects were recorded in 32.0 and 44.7% of the participants, but these were limited to minor local and general reactions. In the present study both preparations were safe and efficient.

Full text

PDF
143

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ambrosch F., Frisch-Niggemeyer W., Kremsner P., Kunz C., André F., Safary A., Wiedermann G. Persistence of vaccine-induced antibodies to hepatitis B surface antigen and the need for booster vaccination in adult subjects. Postgrad Med J. 1987;63 (Suppl 2):129–135. [PubMed] [Google Scholar]
  2. Bergamini F., Zanetti A. Immunogenicity of yeast-derived hepatitis B vaccines in young adults. Postgrad Med J. 1987;63 (Suppl 2):137–138. [PubMed] [Google Scholar]
  3. Davidson M., Krugman S. Immunogenicity of recombinant yeast hepatitis B vaccine. Lancet. 1985 Jan 12;1(8420):108–109. doi: 10.1016/s0140-6736(85)92000-8. [DOI] [PubMed] [Google Scholar]
  4. Frisch-Niggemeyer W., Ambrosch F., Hofmann H. The assessment of immunity against hepatitis B after vaccination. J Biol Stand. 1986 Jul;14(3):255–258. doi: 10.1016/0092-1157(86)90011-9. [DOI] [PubMed] [Google Scholar]
  5. Goudeau A., Denis F., Mounier M., Dubois F., Klein J., Godefroy A., Ballet M., Mountij A. Comparative multicentre study of the immunogenicity of different hepatitis B vaccines in healthy volunteers. Postgrad Med J. 1987;63 (Suppl 2):125–128. [PubMed] [Google Scholar]
  6. Hadler S. C., Francis D. P., Maynard J. E., Thompson S. E., Judson F. N., Echenberg D. F., Ostrow D. G., O'Malley P. M., Penley K. A., Altman N. L. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med. 1986 Jul 24;315(4):209–214. doi: 10.1056/NEJM198607243150401. [DOI] [PubMed] [Google Scholar]
  7. Harford N., Cabezon T., Crabeel M., Simoen E., Rutgers A., De Wilde M. Expression of hepatitis B surface antigen in yeast. Dev Biol Stand. 1983;54:125–130. [PubMed] [Google Scholar]
  8. Hollinger F. B. Hepatitis B vaccines--to switch or not to switch. JAMA. 1987 May 15;257(19):2634–2636. [PubMed] [Google Scholar]
  9. Jilg W., Lorbeer B., Schmidt M., Wilske B., Zoulek G., Deinhardt F. Clinical evaluation of a recombinant hepatitis B vaccine. Lancet. 1984 Nov 24;2(8413):1174–1175. doi: 10.1016/s0140-6736(84)92740-5. [DOI] [PubMed] [Google Scholar]
  10. Milne A., Brawner T. A., Dumbill P. C., Kawachi I., Pearce N. E. Comparison of the immunogenicity of reduced doses of two recombinant DNA hepatitis B vaccines in New Zealand children. J Med Virol. 1989 Mar;27(3):264–267. doi: 10.1002/jmv.1890270314. [DOI] [PubMed] [Google Scholar]
  11. Odaka N., Eldred L., Cohn S., Muñoz A., Fields H. A., Fox R., Solomon R., Kaslow R., Polk B. F. Comparative immunogenicity of plasma and recombinant hepatitis B virus vaccines in homosexual men. JAMA. 1988 Dec 23;260(24):3635–3637. [PubMed] [Google Scholar]
  12. Szmuness W., Stevens C. E., Zang E. A., Harley E. J., Kellner A. A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report. Hepatology. 1981 Sep-Oct;1(5):377–385. doi: 10.1002/hep.1840010502. [DOI] [PubMed] [Google Scholar]
  13. Valenzuela P., Medina A., Rutter W. J., Ammerer G., Hall B. D. Synthesis and assembly of hepatitis B virus surface antigen particles in yeast. Nature. 1982 Jul 22;298(5872):347–350. doi: 10.1038/298347a0. [DOI] [PubMed] [Google Scholar]
  14. Walgate R. Hepatitis B. Taiwan plans mass vaccination. Nature. 1984 Nov 15;312(5991):190–190. doi: 10.1038/312190b0. [DOI] [PubMed] [Google Scholar]

Articles from Epidemiology and Infection are provided here courtesy of Cambridge University Press

RESOURCES